Gemcitabine and Oxaliplatin (GEMOX) in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma
Primary objective:

To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.

Secondary objectives:

To assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC.
Nasopharyngeal Neoplasms
DRUG: Gemcitabine|DRUG: Oxaliplatin
Efficacy: Tumor response rate based on Response Evaluation Criteria in Solid Tumour (RECIST) criteria, Baseline to end of study|Safety: Clinical and laboratory criteria, Baseline to end of study|The incidence of adverse events based on National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0, Baseline to 30 days post treatment|Occurrence of serious adverse events (SAE), Baseline to 30 days post treatment|Drop-out rate, End of study
Toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms., Baseline to end of study
Primary objective:

To evaluate the response rate of biweekly gemcitabine and oxaliplatin (the GEMOX regimen) in the first line treatment of metastatic or recurrent nasopharyngeal carcinoma.

Secondary objectives:

To assess the toxicity, duration of response, time to progression, progression-free survival, overall survival and cancer-related symptoms in the first line treatment of patients with metastatic or recurrent NPC.